Israël - anglais - Ministry of Health

ferring pharmaceuticals ltd - degarelix as acetate - powder for solution for injection - degarelix as acetate 120 mg - degarelix - for the treatment of adult male patients with advanced hormone-dependent prostate cancer.

Israël - anglais - Ministry of Health

ferring pharmaceuticals ltd - degarelix as acetate - powder for solution for injection - degarelix as acetate 80 mg - degarelix - for the treatment of adult male patients with advanced hormone-dependent prostate cancer.

Israël - anglais - Ministry of Health

ferring pharmaceuticals ltd - degarelix as acetate - powder and solvent for solution for infusion - degarelix as acetate 120 mg - degarelix - for the treatment of adult male patients with advanced hormone-dependent prostate cancer.

Israël - anglais - Ministry of Health

ferring pharmaceuticals ltd - degarelix as acetate - powder and solvent for solution for injection - degarelix as acetate 120 mg - degarelix - for the treatment of adult male patients with advanced hormone-dependent prostate cancer.

Israël - anglais - Ministry of Health

ferring pharmaceuticals ltd - degarelix as acetate - powder and solvent for solution for injection - degarelix as acetate 80 mg - degarelix - for the treatment of adult male patients with advanced hormone-dependent prostate cancer.

Israël - anglais - Ministry of Health

ferring pharmaceuticals ltd - degarelix as acetate - powder and solvent for solution for injection - degarelix as acetate 80 mg - degarelix - for the treatment of adult male patients with advanced hormone-dependent prostate cancer.

Union européenne - anglais - EMA (European Medicines Agency)

ferring pharmaceuticals a/s - degarelix - prostatic neoplasms - endocrine therapy - firmagon is a gonadotrophin releasing hormone (gnrh) antagonist indicated:- for treatment of adult male patients with advanced hormone-dependent prostate cancer.- for treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy.- as neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced hormone dependent prostate cancer.

Israël - anglais - Ministry of Health

ferring pharmaceuticals ltd - degarelix as acetate - powder and solvent for solution for injection - degarelix as acetate 120 mg - degarelix - degarelix - for the treatment of adult male patients with advanced hormone-dependent prostate cancer.

Israël - anglais - Ministry of Health

ferring pharmaceuticals ltd - degarelix as acetate - powder and solvent for solution for injection - degarelix as acetate 80 mg - degarelix - degarelix - for the treatment of adult male patients with advanced hormone-dependent prostate cancer.

Irlande - anglais - HPRA (Health Products Regulatory Authority)

sanofi-aventis ireland limited t/a sanofi - piretanide - tablet - 6 milligram(s) - sulfonamides, plain; piretanide